Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

200.91 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
News headline image
Recap: Natera Q4 Earnings ↗
 
Via Benzinga
News headline image
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 28, 2024 ↗
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
News headline image
Earnings Preview For Natera ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
News headline image
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
From Natera, Inc.
Via Business Wire
News headline image
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Natera Through 9 Analysts ↗
 
Via Benzinga
News headline image
There are signs that NASDAQ:NTRA may be ready to breakout. ↗
NATERA INC (NASDAQ:NTRA) has a good technical rating of 10 out of 10 and could possibly break out. 
Via Chartmill
News headline image
Expert Ratings For Natera ↗
 
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
News headline image
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
News headline image
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy ↗
NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending. 
Via InvestorPlace
Topics Bankruptcy
News headline image
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy ↗
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures. 
Via Benzinga
Topics Bankruptcy
News headline image
Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
New Study Validates Signatera™ in Endometrial Cancer
From Natera, Inc.
Via Business Wire
News headline image
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
From Natera, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
From Natera, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Reproductive Health Assets from Invitae
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
News headline image
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle ↗
The company must pay $57 million in damages, but that's far less than expected. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket ↗
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market... 
Via Benzinga
News headline image
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as... 
Via Benzinga
Topics Stocks
News headline image
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
News headline image
Bull of the Day - NeoGenomics ↗
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
News headline image
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.